Sorrento Therapeutics Inc. (SRNE)

Overview

Sorrento Therapeutics, Inc. is a biopharmaceutical company engaged in the development of new therapies for cancer, infectious diseases, and pain across clinical and commercial stages. The company, founded in 2006 and headquartered in San Diego, California, operates primarily through two segments: Sorrento Therapeutics and Scilex. Sorrento Therapeutics is noted for its proprietary G-MAB antibody library and innovative delivery methods aimed at cancer treatment, including CAR-T therapy, bispecific antibodies, and antibody-drug conjugates among others. It also focuses on developing solutions for pain management and has established collaborations for addressing infectious diseases like COVID-19. On February 13, 2023, Sorrento Therapeutics filed for voluntary reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas, which was subsequently approved.

Products and Services

• Anti-CD38 CAR-T Therapy

  This therapy is in development for treating multiple myeloma, amyloidosis, and graft versus host disease. It exemplifies Sorrento's leadership in the CAR-T therapy space, providing hope for improved outcomes in hard-to-treat conditions.

• Sofusa

  A cutting-edge drug delivery technology that directly delivers biologics into the lymphatic system. This technology is part of Sorrento's innovative approach to combating diseases such as melanoma in collaboration with the Mayo Clinic.

• Resiniferatoxin (RTX)

  An investigational non-opioid TRPV1 agonist neurotoxin for managing severe cancer and osteoarthritis pain, demonstrating Sorrento's commitment to addressing the opioid crisis with alternative pain management solutions.

• ZTlido

  A lidocaine topical system designed for the relief of post-herpetic neuralgia, showcasing the company's capabilities in developing and commercializing topically applied products.

• SEMDEXA (SP-102)

  A Phase III clinical trial injectable viscous gel for the treatment of sciatica-related low back pain, highlighting Sorrento's focus on novel treatments in pain management.

• SP-103

  An investigational non-aqueous lidocaine topical system currently undergoing clinical development for chronic low back pain, further emphasizing the company's dedication to non-opioid pain solutions.

• SP-104

  A novel formulation of low-dose delayed-release naltrexone hydrochloride aimed at treating fibromyalgia, reflecting Sorrento's innovative approach to chronic condition management.

• Collaborations for Infectious Disease Treatments

  Partnering with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19 and with Mayo Clinic for a study using Sofusa technology to deliver Ipilimumab in melanoma patients. These collaborations illustrate Sorrento's strategy to extend its therapeutic expertise into infectious disease treatment through partnership and innovation.